Choice of prosthetic heart valve in a developing country

Shiv Kumar Choudhary, Sachin Talwar, Balram Airan

ABSTRACT
Mechanical prostheses and stented xenografts (bioprostheses) are most commonly used substitutes for aortic and mitral valve replacement. The mechanical valves have the advantage of durability but are accompanied with the risk of thromboembolism, problems of long-term anticoagulation, and associated risk of bleeding. In contrast, bioprosthetic valves do not require long-term anticoagulation, but carry the risk of structural valve degeneration and re-operation. A mechanical valve is favoured in young patients (<40 years) if reliable anticoagulation is ensured. In elderly patients (>60 years), a bioprosthesis is a suitable substitute. In middle-aged patients (40–60 years), risk of re-operation in a bioprosthesis is equal to that of bleeding in a mechanical valve. Traditionally, a bioprosthesis is opted in patients with limited life expectancy. Calculation of life expectancy, based solely upon chronological age, is erroneous. In developing countries, the calculated life expectancy is much lower than that of Western population, hence age related Western cut-offs are not valid in developing countries. Besides age, cardiac condition of the patient, systemic illnesses, socio-economic status, gender and geographical location also decide the life expectancy of the patients. Selection of the prosthetic valve substitute should be based on: aspiration of the patient, life expectancy, socio-economic and educational background, occupation of the patient, availability, cost, monitoring of anti-coagulation, monitoring of valve function and other valve related complications, and possibility of re-operation.

INTRODUCTION
The surgical replacement of diseased heart valves is based on the premise that the prosthesis chosen to replace a diseased heart valve will improve or prevent further deterioration of heart function, relieve symptoms, improve functional status, and prolong overall survival. Thus, it is a trade-off between the natural course of the disease and the risks of surgery and the recognised complications of prosthetic heart valves. Among the available valve substitutes, none is closest to being ‘ideal’. Each valve substitute has some inherent advantages and disadvantages, and is not suitable for all patient subgroups. Mechanical prostheses and stented xenografts (bioprostheses) are the most commonly used substitutes for aortic and mitral valve replacement (MVR). In addition, for aortic valve replacement (AVR), autograft/homograft or stentless xenografts are other options. However, because of their limited availability, technical complexity, and difficult reoperations, autograft/homograft and stentless xenografts are used for specific indications in a limited subset of patients. Thus, in most circumstances, the choice remains between a mechanical valve and a bioprosthesis.

Easy availability and durability are the advantages of the mechanical valves. However, mechanical valves require lifelong anticoagulation. Thus, mechanical valves impose the mortality and morbidity related to anticoagulation. On the other hand, with a bioprosthesis, anticoagulation is usually not required after a period of 3–6 months. However, depending upon the age at implantation and the type of bioprosthesis, it starts degenerating after 5–10 years. Hence, if the patient survives long enough, there is a mandatory risk of reoperation.

Various factors that need to be considered at the time of selection of a prosthesis are listed in table 1. The most important factors that should be considered are the patient’s age, life expectancy, preference, indication/contraindication/acceptance for warfarin therapy, the patient’s tolerance to the need for repeat valve replacement, and comorbidities.

POINTS OF CONSENSUS
Choosing the most suitable prosthetic heart valve should be a shared decision-making process that accounts for the patient’s values and preferences, with full disclosure of the indications for and the risks of anticoagulant therapy and the potential need for and risk of reoperation. A mechanical valve is favoured in: (1) an informed patient who wants a mechanical valve and has no contraindication to long-term anticoagulation; (2) the patient who is already on anticoagulation (mechanical prosthesis in another position or at high risk for thromboembolism); (3) the patient who is at risk of accelerated bioprosthesis structural deterioration (young age, hyperparathyroidism, renal insufficiency); and (4) the patient with a long life expectancy. In younger patients, bioprostheses degenerate much faster, and if a bioprosthesis is used in younger patients (<40 years), they will require multiple reoperations. Each subsequent reoperation entails operative risk much higher than the previous one. Thus, the risk of reoperations becomes prohibitive. It is also accompanied with the burden of cost of multiple reoperations. Therefore, in this age group a mechanical valve is the well-accepted option in most patients. On the other hand, a bioprosthesis may be preferred in: (1) an informed patient who wants a bioprosthesis; (2) patients where anticoagulation is not desired (lifestyle), not feasible (compliance problems, availability or monitoring issues) or is contraindicated; (3) a female patient of childbearing age with a history of...
required.

II. Is life expectancy dependent only upon chronological age?

III. Is there any distinct advantage of using a mechanical valve in middle-aged patients <60 years of age, a mechanical prosthesis is considered reasonable. However, this approach is not supported by robust evidence and raises three important questions:

- Is there any distinct advantage of using a mechanical valve in middle-aged patients (40–60 years)?
- Is life expectancy dependent only upon chronological age?
- Is the cut-off age of 60–65 years in the current American and European guidelines applicable to developing countries?

MECHANICAL VALVE VERSUS STENTED BIOPROSTHESIS

The advantageous durability of mechanical valves is offset by the risk of thromboembolism, the need for long-term anticoagulation, and associated risk of bleeding. In contrast, bioprosthetic valves do not require long-term anticoagulation, but carry the risk of structural failure and reoperation. To answer the question regarding the superiority of one type of valve over another, there is a need for robust long-term outcome data using the current generation of bioprosthesis/mechanical valves in both the aortic and the mitral position in large numbers of patients of all age groups. However, no such data are available. In the absence of large, multicentred, randomised clinical trials, inferences are drawn from the existing literature, an approach which has several shortcomings. Minimal data are available about the use of newer bioprostheses. Most of the published reports related to bioprostheses pertain to the elderly (>60 years) population. Very few reports are available pertaining to the use of bioprostheses in middle aged (40–60 years) subjects. Similarly, most of the published reports address the aortic valve. There is a paucity of long-term results on MVR with bioprostheses or mechanical valves. Finally, almost negligible information is available from developing countries. All the major studies are from the developed world. In the absence of perfect data, we will build our case using available evidence.

Bleeding and anticoagulation

Need for life-long oral anticoagulation and associated bleeding complications are the major drawbacks of mechanical valves. Stented bioprostheses also need oral anticoagulants in the early phase. Some patients with bioprostheses may continue to receive oral anticoagulants for an extended period for indications not related to bioprostheses. In its present form, oral anticoagulation therapy is accompanied by several problems.

Anticoagulation therapy, not infrequently, results in internal or external bleeding episodes that can cause death, stroke, reoperation and hospitalisation. With an international normalised ratio (INR) of 2.0–3.0, the annual risk of a major bleeding episode is approximately 1–2% per patient-year. The two earliest randomised controlled trials (the Veterans Affairs study and the Edinburgh study) showed statistically significant increases in bleeding with mechanical valves. Risk of bleeding is higher in patients with mechanical valves requiring higher anticoagulation. In micro-simulation, the simulated lifetime risk of bleeding was 12% with a bioprosthesis valve versus 41% with a mechanical valve for a 60-year-old man. The risk of bleeding is much higher in elderly patients. In patients with mechanical valves and the same level of anticoagulation therapy, patients >60 years of age had up to seven times higher bleeding rates than patients <60 years of age. Among patients 75 years of age, the bleeding rate was greatly increased in those with a mechanical valve compared with those who received a bioprosthesis (OR 18.9, 95% CI 2.2 to 163.0; p=0.007).

Major bleeding episodes are associated with very high (13–22%) mortality. It is difficult to maintain an adequate INR in the therapeutic range. In developed countries, with better and more frequent anticoagulation monitoring, the INR could be maintained in the therapeutic range in 40–60% of patients. In developing countries, however, where patients from remote areas travel to cities once or twice a year for anticoagulation monitoring, this figure is as low as 25%. Patients who are not within the therapeutic range are exposed to bleeding risk if the INR is higher, or thromboembolism if the INR is lower. Patients with bioprostheses either do not need anticoagulation or require a lower degree of anticoagulation without the risk of valve thrombosis. Hence, patients with bioprostheses are not exposed to these risks.

There are other major problems associated with lifetime anticoagulation therapy including frequent blood draws, drug–drug interactions, dietary and activity restrictions, and the cost of medicine. In developing countries, patients have to travel long distances for anticoagulation monitoring, resulting in vocational losses. Oral anticoagulants may have to be discontinued, for at least a period of time, because of major bleeding, or because of the need for non-cardiac surgical/non-surgical procedures. This exposes patients to the risks of thromboembolism and of mechanical prosthetic heart valve thrombosis, and resultant heart failure, embolism, and mortality.

A special mention is required about those patients who need anticoagulation for atrial fibrillation (AF) or any other indication.
not related to valve prosthesis. Some investigators would support the use of a mechanical valve in such cases as the patient is already on oral anticoagulants for AF. Several factors need to be considered before adopting such an approach. Firstly, a patient with AF requires a lower INR compared with a patient with a mechanical valve, especially in the mitral position. Secondly, a patient with a mechanical valve requires a much higher INR in the presence of AF, and thus bleeding risk increases exponentially. Thirdly, recently introduced direct thrombin inhibitors and factor Xa inhibitor can be used to treat AF, but are not recommended for mechanical valves. Lastly, in some cases, it is possible to treat AF with surgical or catheter intervention. Thus, it may not be prudent to commit a patient to lifetime anticoagulation by choosing a mechanical valve for AF only.

### Structural valve deterioration and reoperations

All available bioprostheses develop structural valve deterioration (SVD) and ultimately fail. Major risk factors for SVD are listed in the table 2. SVD is strongly influenced by the age of the patient at the time of implantation (table 3).

Patients >65 years of age have a much lower rate of SVD than those <65 years. The cumulative 15- to 20-year risk of SVD at implantation of 60 and 55 years of age averages 25% and 34%, respectively. Burdon and colleagues found that after 15 years of follow-up, only a third of patients who had received a bioprosthesis for AVR between the ages of 16–39 years remained free of SVD, compared with more than 90% of those over 70 at the time of implantation. The Edinburgh trial found an increased risk of porcine valve failure in younger patients with a relative risk of approximately 1.5 for every 10 years of age. SVD after MVR with first generation porcine bioprostheses begins at about 5 years, and at about 8 years after AVR. After 10 years of AVR, SVD begins to have a deleterious effect on survival.

Advances in tissue fixation and anti-calciﬁcation treatment have resulted in current-generation bioprostheses that have superior durability compared with the ﬁrst generation bioprostheses. The second generation Hancock II aortic valve had 81±5% freedom from SVD after 15 years in patients with a mean age of 65 years at the time of implantation, which was better than 57±4% freedom from SVD at 15 years in patients with a mean age of 69 years using the ﬁrst-generation Hancock bioprosthesis. Similarly, the Carpentier-Edwards pericardial aortic valve had 94% freedom from SVD at 10 years and 77% at 15 years in patients with a mean age of 65 years. After MVR in patients <60 years of age, SVD at 10 years was 16±3.7% with the C-E pericardial valve versus 35.3±3.3% with the C-E porcine valve (p<0.05); and SVD at 10 years for patients 61–70 years of age was 4.8±2.1% with the C-E pericardial valve versus 24.8±3.7% with the C-E porcine valve (p<0.05). The third-generation bioprostheses are even more durable, with 92±8% freedom from SVD 12 years after implantation of an aortic bioprosthesis in patients with a mean age of 54 years at the time of surgery. Current bioprostheses are signiﬁcantly more durable in the aortic position than in the mitral position (14.3±6.8% more freedom from 15-year reoperation; p<0.018).

Minimal data are available on the use of second generation and newer bioprostheses in middle aged persons. From the data available, it can be inferred that if a second generation bioprosthesis is used in a patient 40 years of age, on average it is going to fail at 10 years in the mitral position, and at 12 years in the aortic position. Third generation bioprostheses are expected to last a little longer, more so in older patients (50–60 years).

If patients survive long enough, eventually all those with bioprostheses will need to undergo reoperation. If patients are operated on between 40 and 60 years of age, the linearised reoperation rate ranges from 3.5% to 4.3% per patient-year. For the first 8–10 years reoperation is rarely required, but almost all these patients will require reoperation after 12–20 years of follow-up. Chan et al reported that the median interval to reoperation in patients undergoing AVR with current generation stented aortic bioprostheses was 7.7 years in patients aged <40 years, and 12.9 years in patients between 40 and 60 years of age. The actuarial freedom from structural valve degeneration and reoperation, in patients <40 years of age who underwent mostly MVR with the Hancock II porcine bioprosthesis, was 70.6±5.2% and 66±5.7%, respectively. No valve was explanted for structural degeneration within 5 years.

The mortality rate for the first reoperation at the age of 50–65 years ranges from 5% to 7%, 13–17 The mortality for a second reoperation in elderly patients is about 12%. However, mortality from reoperation secondary to bioprosthetic aortic structural failure can be lowered by reoperation in patients with low, rather than high, New York Heart Association (NYHA) functional class.

In real life, not all patients with a bioprosthesis require reoperation. Though sufﬁcient data are not available in younger patients, limited life expectancy related to age precludes reoperation in the majority of cases. Life expectancy after aortic bioprosthesis implantation at age 60, 65, 70, and 75 years are 15, 12, 10, and 7 years, respectively; the risks of SVD at these ages is 25%, 18%, 10%, and 5%, respectively. Thus, if 100 patients had bioprostheses initially, the number of patients who will need reoperation in these age groups will be 4, 3, 1, and <1, respectively.

Mechanical valves are also not free from reoperations. The annual risk of reoperation for mechanical valves ranges from 0.3% to 1.2%. In contrast to bioprostheses, there is a constant hazard of reoperation with mechanical valves. If

---

### Table 2 Risk factors for bioprosthesis structural valve degeneration

| Serial number | Risk factor                      |
|---------------|---------------------------------|
| 1             | Younger age at implantation      |
| 2             | Mitral position                  |
| 3             | Older generation of bioprosthesis|
| 4             | Renal insufficiency              |
| 5             | Hyperparathyroidism              |
| 6             | Hypertension                     |
| 7             | Left ventricular hypertrophy     |
| 8             | Left ventricular dysfunction     |

### Table 3 Durability of bioprosthetic valves in the aortic position as a function of the age of the patient

| Age (years) | 5 years (%) | 10 years (%) | 15 years (%) |
|------------|-------------|--------------|--------------|
| <35        | 79          | 51           |              |
| 36–50      | 99          | 68           | 48           |
| 51–64      | 98          | 72           | 42           |
| 65–69      | 98          | 74           | 64           |
| >70        | 100         | 90           | 90           |

---

Choudhary SK, et al. Heart Asia 2016;8:65–72. doi:10.1136/heartasia-2015-010650
operated on between 40 and 60 years of age, the linearised reoperation rate ranges from 0.2% to 0.6% per patient-year. 

Similarly, in patients 61–70 years of age, the 15-year actuarial freedom from reoperation was 82.2% for mechanical valves.

Most of the mechanical valves needed emergency reoperations for valve thrombosis and had a very high mortality rate of 20–24%. 

When considering the possibility of reoperation at the time of prosthesis selection, the future availability of valve-in-valve transcatheter aortic/mitral valve replacement for degenerated bioprosthesis should also be considered. Transcatheter valve insertion in degenerated bioprosthesis, both in the aortic and mitral positions, has shown promising results. There are technical and cost limitations at present. Patients who receive bioprosthetic valves now will likely develop SVD in the next 10–15 years. With technological advances, and large numbers of implants, transcatheter valve implantation will become a safe and viable option.

Valve thrombosis, thromboembolism, stroke, and other events

Thrombosis of a mechanical valve may occur as a catastrophic event with the acute onset of heart failure, pulmonary oedema or cardiogenic shock. Acute valve thrombosis requires urgent thrombolytic therapy or emergency surgery, but mortality remains high. The incidence of obstructive valve thrombosis varies between 0.3% and 1.3% per patient-year and is higher in the mitral position. 

All prosthetic valves are susceptible to formation of thrombus that can subsequently embolise and can result in stroke or loss of function of other organs. The incidence ranges from 0.6% to 2.3% per patient-year. Though several studies report similar incidences of thromboembolism among mechanical valves and bioprostheses, others have reported a higher risk of thromboembolism in patients with a mechanical valve, especially in the mitral position.

No differences in stroke rates were observed in patients with bioprosthetic valves compared with mechanical valves. The 15-year cumulative incidence of stroke was 7.7% (95% CI 5.7% to 9.7%) in the bioprosthesis group and 8.6% (95% CI 6.2% to 11.0%) in the mechanical prosthesis group (HR 1.04, 95% CI 0.75 to 1.43). Most large series have found the incidence of prosthetic valve endocarditis to be the same whether a mechanical or bioprosthetic aortic valves irrespective of age.

Survival

Two large historical randomised clinical trials compared the outcomes after valve replacement with a first-generation porcine heterograft and the original Bjork-Shiley tilting-disc mechanical valve: the Edinburgh Heart Valve Trial conducted between 1975 and 1979 with an average follow-up of 12 years; and the Veteran Affairs (VA) Cooperative Study on Valvular Heart Disease, conducted between 1979 and 1982 with an average follow-up of 13 years. The Edinburgh study showed no difference in mortality at 20 years between mechanical valve and biological valve (23.0% vs 22.6%, p=0.39). In the VA study, there were similar outcomes at 5 and 11 years, but after 15 years follow-up all-cause mortality after AVR was lower with the mechanical valve (66% vs 79%, p=0.02) but not after MVR (81% vs 79%, p=0.30). The VA trial had several other important findings: (1) the majority (60%) of the deaths after AVR were not related to the prosthesis, but to the associated comorbid conditions; and (2) survival in the first 8 years after valve replacement was virtually identical for mechanical and porcine valves. Thus, in the patient with no comorbid conditions, survival at 10 years would be similar whether a mechanical or a bioprosthetic valve was used.

These trials had several limitations. Both the trials studied first-generation porcine bioprostheses and the Bjork-Shiley mechanical valve, all of which are now obsolete. The patient populations were also heterogeneous without any focus on specific age group. By present standards, perioperative mortality was also extremely high (15.5% in MVR). Thus, extrapolation of these data to modern practice should be done with caution. The most recent randomised clinical trial, using newer bioprostheses and mechanical valves in the aortic position, was performed between 1995 and 2003. At 13-year follow-up, there was no difference in overall mortality (biological vs mechanical: 27.5% vs 30.6%), valve-related mortality (6.7% vs 8.1%), and cardiac-related mortality (16.7% vs 21.7%).

There are several retrospective studies which showed improved survival with mechanical valves. However, most of the larger series reported either no difference in early and late mortality or improved survival with bioprostheses.

A recent systemic review and meta-analysis did not find any difference in risk factor-corrected overall death rate between mechanical or bioprosthetic aortic valves irrespective of age. Similarly, in a large retrospective study, Chan et al. compared mechanical and tissue AVR in 3062 patients with a combined follow-up of 22 182 patient-years. They did not find any difference in valve related mortality in both the groups in patients >40 years of age (table 5). Ruel and colleagues reported no significant prosthesis- or age-related differences in late survival after bioprosthetic or mechanical valve implantation in patients <60 years of age.

---

**Table 4** Linearised (%/patient-year) rate of composite valve-related morbidity by age, and actuarial freedom from valve related morbidity at 15 years

| Age (years) | Valve related morbidity | Actuarial freedom from valve related morbidity at 15 years |
|------------|-------------------------|----------------------------------------------------------|
|            | Bioprosthesis (B) | Mechanical (M) | B vs M p values | Bioprosthesis (B) | Mechanical (M) | B vs M p values |
| ≤40        | 0.0                    | 0.8            | 0.011             | 97.6±1.1%        | 85.4±2.5%        | <0.001            |
| 41–50      | 0.0                    | 1.3            | <0.001            | 95.6±1.1%        | 81.5±3.7%        | <0.001            |
| 51–60      | 0.3                    | 2.2            | <0.001            | 97.6±1.1%        | 85.4±2.5%        | <0.001            |
| 61–70      | 0.4                    | 2.7            | <0.001            | 95.6±1.1%        | 81.5±3.7%        | <0.001            |
Table 5  Incidence of valve related mortality, and actuarial freedom from valve related morbidity and mortality at 15 years

| Age (years) | Valve related mortality Bioprosthesis (B) | Mechanical (M) | B vs M p value | Actuarial freedom from valve related mortality at 15 years Bioprosthesis (B) | Mechanical (M) | B vs M p value |
|-------------|-------------------------------------------|----------------|----------------|---------------------------------------------------------------------|----------------|----------------|
| ≤40         | 1.1                                       | 0.0            | 0.003          | 91.8%±2.4%                                                          | 94.1%±2.6%     | 0.76           |
| 41–50       | 0.8                                       | 0.5            | 0.516          | 91.8%±2.4%                                                          | 94.1%±2.6%     | 0.76           |
| 51–60       | 0.6                                       | 0.5            | 0.646          | 82.8%±2.7%                                                          | 89.3%±3.3%     | 0.37           |
| 61–70       | 1.0                                       | 1.1            | 0.738          |                                                                      |                |                |

The major cause of mortality in bioprostheses is reoperation, whereas the major cause of death in patients with mechanical valves is anticoagulation related complications. Valve thrombosis and emergency surgery also contributes to mortality in mechanical valves. Van Geldorp et al. showed that at 55 years of age, the risk of subsequent reoperation with a bioprosthesis is equal to that of bleeding with a mechanical valve. Similar findings were also reported by others. Although no significant difference has been found in overall survival after bioprosthesis or mechanical valve implantation, there is sufficient evidence to show that the use of a bioprosthesis is associated with better event-free survival. Similarly, use of a bioprosthesis is associated with less valve related morbidity (table 4).

Life expectancy
A bioprosthesis is opted for when the presumed durability of the bioprosthesis is more than the life expectancy of the patient. However, when deciding the life expectancy, traditionally and unintentionally, it is always considered equivalent to the average life expectancy in developed nations. Though the guidelines also mention country and patient-specific life expectancy, it is rarely followed in clinical practice; erroneously, it is assumed that all patients are going to survive up to the age of 75–80 years. While deciding the patient’s life expectancy, several factors should be taken into consideration.

Relative survival
The presence of valvular heart disease, even after valve replacement, affects survival adversely. Relative survival is a measure of the excess mortality among heart valve replacement patients compared with the general population. The relative survival rate is defined as the ratio of the observed survival in a group of patients during a specified time interval to the survival expected from the general population experience. Lindblom and colleagues have shown that relative survival in patients undergoing AVR and MVR was only 78% and 65%, respectively. Relative survival is less in younger patients. The presence of higher NYHA functional class and/or AF further reduces the expected survival. At 10-year follow up, the presence of NYHA functional class III/IV and AF increases the mortality by 32% and 40%, respectively. The presence of aortic regurgitation and mitral regurgitation also contribute to excess mortality. Simulated models have shown that the calculated life expectancy of a 60-year-old patient receiving a bioprosthesis is 11.9 years. This is much shorter than the life expectancy of 22.6 years for 60-year-olds reported by the US National Center for Health Statistics.

Biological factors affecting survival
Besides the chronological age of patients, several cardiac and non-cardiac factors decrease their life expectancy (table 6). Left ventricular dysfunction, tricuspid valve disease, pulmonary arterial hypertension, higher NYHA functional class, and AF represent advanced valvular heart disease and are associated with reduced survival. Thus, at a given point, age is not the only determinant of life expectancy. In developing countries, even young patients can present with a very advanced stage of valvular heart disease. The life expectancy of these patients is much lower than the national average.

Socioeconomic factors affecting survival
While considering the patient’s life expectancy, it is important to consider the country/region/gender-specific life expectancy. The average life expectancy of a person in India is much less than that of someone in the USA. In 2004, the average predicted life expectancy at birth of an Indian and a US citizen were 62.2 years and 78 years, respectively. Also, in India the average life expectancy varies greatly among different states (table 7). Kerala, with better health infrastructure and higher

| Table 6  Cardiac and non-cardiac factors which predict reduced survival  

| Serial number | Cardiac factor | Non-cardiac factor |
|---------------|----------------|-------------------|
| 1             | Left ventricular dysfunction | Impaired renal function |
| 2             | Severe pulmonary arterial hypertension | Diabetes |
| 3             | Tricuspid valve involvement | Hypertension |
| 4             | Atrial fibrillation | Smoking |
| 5             | Cardiomegaly | Lung disease |

| Table 7  Life expectancy at birth in 2004 in different Indian states  

| State | Life expectancy at birth (years) |
|-------|---------------------------------|
| Kerala | 74.0 |
| Punjab | 69.2 |
| Gujarat | 64.2 |
| Bihar | 61.2 |
| Jharkhand | 58.0 |
Thus, when selecting the prosthesis, life expectancy should be taken into account. Younger patients with limited life expectancy usually benefit from mechanical valves because of lower risk of reoperation. In contrast, bioprostheses have a slower rate of structural valve degeneration (SVD). The mortality of reoperation with a bioprosthetic valve is equal to that of bleeding with a mechanical valve. Hence, there is no survival difference in patients older than 40 years who receive either a bioprosthetic or a mechanical valve.

SVD is a function of the patient’s age. In the middle aged population, SVD starts at about 5 years in the mitral position and at 8 years in the aortic position, and patients will usually require the first elective reoperation after 10–12 years. Newer bioprostheses have a slower rate of SVD. The mortality of reoperation with a bioprosthesis has diminished to 5–7%. In the case of mechanical valves, bleeding episodes are associated with very high mortality. In addition, there is a low but constant risk of emergency reoperation. Mortality from reoperation in patients with mechanical valves is much higher. Mechanical valves are also associated with higher valve related morbidity and problems of anticoagulation.

The calculation of life expectancy, based solely upon chronological age, is erroneous. In developing countries, the calculated life expectancy is much lower than that of Western populations. Hence, age-related Western cut-offs are not valid in developing countries. Besides age, the cardiac condition of the patient, systemic illnesses, socioeconomic status, gender, and geographical location also dictate the life expectancy of the patient. In developing countries, patients from rural backgrounds and low socioeconomic status often present with advanced disease. Despite being young in age, the life expectancy of these patients is limited. Thus, when selecting the prosthesis, life expectancy should be calculated using all the relevant factors, rather than age alone.

CHOICE OF PROSTHESSES

As discussed above, the choice of prosthetic heart valve should be a shared decision-making process that accounts for the patient’s values and preferences, with full disclosure of the indications for and risks of anticoagulant therapy and the potential need for and risk of reoperation. The main determinants of valve selection are the individual patient’s life expectancy, the patient’s tolerance for repeat valve replacement, and the use of oral anticoagulants with its associated changes in lifestyle.

For the purpose of prosthesis selection, patients can be grouped on the basis of life expectancy. Patients with long life expectancy (more than 20–25 years), depending upon chronological age, will require more than one reoperation if a bioprosthesis is implanted. Patients with limited life expectancy (10–15 years) will require only one reoperation if a bioprosthesis is implanted at the initial operation. A mechanical valve is reasonable in a patient with long life expectancy when there is no contraindication to oral anticoagulants and reliable, quality anticoagulation can be ensured. However, if anticoagulation is either not desired because of lifestyle/profession, or not feasible (compliance problems, availability or monitoring issues), a bioprosthesis is the valve of choice. In patients with limited life expectancy, a bioprosthesis may be considered safely. In patients with moderate life expectancy, because there is no significant survival benefit associated with one prosthesis type over another, decision making is focused on lifestyle considerations, including the burden of anticoagulation medication and monitoring, and the relative risks of major morbidity—primarily stroke, reoperation, and major bleeding events. Thus, a careful evaluation is required, judging the risk of one reoperation with a bioprosthesis vis-à-vis risk and the problems of life-long anticoagulation. Availability, monitoring, cost, lifestyle, profession, and socioeconomic background should be carefully considered before planning life-long anticoagulation. Table 9 lists the factors that make anticoagulation difficult.

### Table 8: Life expectancy at birth (years) in 2004 by gender and location in India

| Location | Gender | Person |
|----------|--------|--------|
| Urban    | 66.0   | 67.6   |
| Rural    | 60.1   | 60.9   |
| Combined | 61.3   | 62.2   |

### Table 9: Factors which make reliable, quality anticoagulation difficult

| Serial number | Factors                          |
|---------------|----------------------------------|
| 1             | Rural background                 |
| 2             | Underdeveloped region            |
| 3             | Inadequate medical services      |
| 4             | Non-availability of anticoaguants |
| 5             | Manual labourer                  |
| 6             | Female gender                    |
| 7             | Non-earning status in family     |
| 8             | Poor socioeconomic status        |
| 9             | Lack of education                |
| 10            | Mental illness                   |

The index case

A 44-year-old manual labourer from a village in India presented with progressive dyspnoea on exertion of 2 years duration. Two months before presentation, he had stopped going to work because of his dyspnoea. He was diagnosed as having a calcific mitral valve with severe stenosis (mitral valve area 0.8 cm²) and mild regurgitation. He had moderate pulmonary artery hypertension. His aortic and tricuspid valves were normal. He had no coronary artery disease and was in sinus rhythm. He was referred for valve replacement surgery.
Should this patient receive a mechanical valve or a bioprosthesis? When choosing a prosthetic valve for this patient, several issues need to be taken into consideration. Important considerations are: life expectancy of the patient; occupation of the patient; availability, cost, and monitoring of anticoagulation; monitoring of valve function and other valve related complications; and the possibility of re-operation. The predicted life expectancy of a manual labourer from rural India at this age would range from 20 to 25 years. The relative survival of patients with MVR ranges from 70% to 80%. As this patient does not have any other risk factor predicting reduced survival, the life expectancy of this patient could be assumed to be 14 to 20 years. Being a manual labourer, this patient is prone to repeated injuries and thus is at an increased risk of life-threatening haemorrhage due to the use of anticoagulants that are mandatory with a mechanical valve. As the patient is a resident of a village, he is unlikely to have access to a health facility where his anticoagulation status can be reliably monitored. A mechanical valve also requires frequent assessment with cinefluoroscopy/echocardiography. In a rural setting these facilities are unlikely to be available. In addition to the costs, the patient will be required to travel frequently to a town/city for these investigations. This will keep him away from work that will adversely impact his already compromised economic status and burden him further. As medical practitioners in rural India frequently may not fully understand the consequences of using oral anticoagulants, management of other concurrent illnesses will also become difficult. In contrast, a bioprosthesis eliminates the risks of sudden prosthetic valve dysfunction and death, reduces the risk of anticoagulation related haemorrhage, avoids repeated visits to the hospital, reduces the costs of treatment, and is associated with an acceptable quality of life. The currently available bioprostheses are expected to last for 10–12 years in this patient. He can safely undergo a reoperation once valve deterioration occurs later in life. Developments in tissue valves and transcatheter valve technology are expected to last for 10 years. An acceptable quality of life. The currently available bioprostheses are expected to last for 10 years. A tissue valve appears to best serve the needs of this patient.

**Provenance and peer review.** Commissioned; externally peer reviewed.

**REFERENCES**

1. Harken DE. Heart valves: ten commandments and still counting. Ann Thorac Surg 1989; 68(Suppl 3):518–19.
2. Huang G, Rahimtoola SH. Prosthetic heart valve. Circulation 2011; 123:2602–5.
3. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:2440–92.
4. Burdon TA, Miller DC, Oyer PE, et al. Durability of porcine valves fifteen years in a representative North American patient population. J Thorac Cardiovasc Surg 1992; 103:238–51.
5. Hoffmann G, Lutter G, Cremer J. Durability of bioprosthetic cardiac valves. Dtsch Arztebl Int 2008; 105:143–8.
6. Vahanian A, Alfieri O, Andreotti F, et al., Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33:2451–96.
7. EL Oakley R, Kliene P, Bach DS. Choice of prosthetic heart valve in today’s practice. Circulation 2008; 117:253–6.
8. Rahimtoola SH. Choice of prosthetic heart valve for adult patients. J Am Coll Cardiol 2003; 41:939–904.
9. Bach DS. Choice of prosthetic heart valves: update for the next generation. J Am Coll Cardiol 2002; 40:1717–19.
10. [No authors listed]. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial. Lancet 1996; 348:633–8.
11. Oxenham H, Bloomfield P, Wheatley DJ, et al. Twenty year comparison of a Björk-Shiley mechanical heart valve with porcine bioprostheses. Heart 2003; 89:715–21.
12. Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000; 36:1152–8.
13. Vesev JM, Otto CM. Complications of prosthetic heart valves. Curr Cardiol Rep 2004; 6:106–11.
14. van Geldorp MW, Eric Jamieson WR, Kappestein AP, et al. Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: weighing lifetime anticoagulant related event risk against reoperation risk. J Thorac Cardiovasc Surg 2009; 137:881–6.
15. Aupart M, Diemont F, Babuty D, et al. Results intermedières avec la prostèses valvulaire a ailettes carbomedics. Arch Mal Coeur Vaiss 1997; 90:457–62.
16. Florath I, Alber A, Rosenfeld U, et al. Mid-term outcome and quality of life after aortic valve replacement in elderly people: mechanical versus stentless biological valves. Heart 2005; 91:1023–9.
17. Chang YP, Chikwe J, Moskowitz AJ, et al. Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years. JAMA 2014; 312:1323–9.
18. Petersen P, Grind M, Alder J, SPORTIF II Investigators. Ximelagatran versus fixed-dose warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-gauging, tolerability, and safety study. J Am Coll Cardiol 2003; 41:1445–51.
19. Kimmell SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007; 167:229–35.
20. Al Hales Z. The choice of valve prosthesis: are the guidelines for everyone? Asian Cardiovasc Thorac Ann 2007; 15:457–8.
21. Dürßelman N, Pellerin M, Bouchard D, et al. Prosthetic valve replacement: twenty-year experience at the Montreal Heart Institute. J Thorac Cardiovasc Surg 2004; 127:1388–92.
22. Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol 2010; 55:2413–26.
23. Bonov RO, Carabella BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114:848–231.
24. Jamieson WR, Carter PC, Allard M, et al. Surgical management of valvular heart disease 2004. Can J Cardiol 2004; 20(Suppl E):T7–1208.
25. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thorac Surg 2002; 79:1072–80.

**Key messages**

- Calculation of life expectancy, based solely upon chronological age, is erroneous. Age related Western cut-offs are not valid in developing countries. Besides age, cardiac condition of the patient, systemic illnesses, socio-economic status, gender and geographical location also decide the life expectancy of the patients.
- Selection of the prosthetic valve substitute should be based on: aspiration of the patient, life expectancy, socio-economic and educational background, occupation of the patient, availability, cost, monitoring of anti-coagulation, monitoring of valve function and other valve related complications, and possibility of re-operation.

**Contributors** SKC: primary author, planning and writing the manuscript. ST: revising the work critically for important intellectual content, and final approval of the version submitted. BA: revising the work critically for important intellectual content, and final approval of the version submitted.

**Competing interests** None declared.

Choudhary SK, et al. Heart Asia 2016;8:65–72. doi:10.1136/heartasia-2015-010650
26 Ruel M, Kulik A, Rubens FD, et al. Late incidence and determinants of reoperative patients with prosthetic heart valves. *Eur J Cardiothorac Surg* 2004;25:364–70.

27 Jamieson WR, Ling H, Burr LH, et al. Carpenter-Edwards supraannular bioprostheses evaluation over 15 years. *Ann Thorac Surg* 1998;66(6 Suppl):S49–52.

28 David TE, Ivanov J, Armstrong S, et al. Late results of heart valve replacement with the Hancock II bioprosthesis. *J Thorac Cardiovasc Surg* 2001;121:268–78.

29 Cohn LH, Collins JJ Jr, Rizzo RJ, et al. Twenty-year follow-up of the Hancock modified orifice porcine aortic valve. *Ann Thorac Surg* 1998;66(Suppl):S30–4.

30 Banbury MK, Cosgrove DM III, White JA, et al. Age and valve size effect on the long-term durability of the Carpenter-Edwards aortic porcicular bioprosthesis. *Ann Thorac Surg* 2001;72:753–7.

31 Jamieson WRE, Marchand A, Pelletier CL, et al. Structural valve deterioration in mitral replacement surgery. Comparison of Carpenter-Edwards supra-annular porcine and Perimount pericardial. *J Thorac Cardiovasc Surg* 1999;118:297–305.

32 Bach DS, Metras J, Doty JR, et al. Freedom from structural valve deterioration among patients 60 years of age and younger undergoing Freestyle aortic valve replacement. *J Heart Valve Dis* 2007;16:649–55.

33 Chan V, Jamieson WR, Germain E, et al. Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after aortic valve replacement. *J Thorac Cardiovasc Surg* 2006;131:1267–73.

34 Chan V, Lam BK, Rubens FD, et al. Long-term evaluation of biological versus mechanical valve use at reoperative aortic valve replacement. *J Thorac Cardiovasc Surg* 2012;144:146–51.

35 Chan V, Malas T, Lapierre H, et al. Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after aortic valve replacement. *J Thorac Cardiovasc Surg* 2006;131:1267–73.

36 Roques F, Michel P, Gladstone AR, et al. The Logistic EuroSCORE. *Eur Heart J* 2003;24:1–2.

37 Potter DD, Sundt TM III, Zehr PJ, et al. Operative risk of reoperative aortic valve replacement. *J Thorac Cardiovasc Surg* 2005;129:94–103.

38 Jamieson WRE, Burt LH, Miyagishima RT, et al. Re-operation for bioprosthetic aortic structural failure—risk assessment. *Eur J Cardiothorac Surg* 2003;24:873–8.

39 Kaneko T, Cohn LH, Arantki SF. Tissue valve is the preferred option for patients aged 60 and older. *Circulation* 2013;128:1365–71.

40 Ruel M, Chan V, Bédrard P, et al. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults <60 years of age. *Circulation* 2007;116(11 Suppl):S30–40.

41 Prasongsukarn K, Jamieson WR, Lichtenstein SV. Performance of bioprostheses and mechanical prostheses in age group 61–70 years. *J Heart Valve Dis* 2005;14:501–11.

42 Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. *Heart* 2007;93:137–42.

43 Pibarot P, Demers JL. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. *Circulation* 2009;119:1034–48.

44 Kulik A, Bédrard P, Lam BK, et al. Mechanical versus bioprosthetic valve replacement in middle-aged patients. *Eur J Cardiothorac Surg* 2006;30:485–91.

45 Grover FL, Cohen DJ, Oprian C, et al. Determinants of the occurrence of and survival from prosthetic valve endocarditis: experience of the Veterans Affairs Cooperative Study on Valvular Heart Disease. *J Thorac Cardiovasc Surg* 1994;108:207–14.

46 Sabik JF, Lyle BW, Blackstone EH, et al. Aortic root replacement with cryopreserved allograft for prosthetic valve endocarditis. *Ann Thorac Surg* 2002;74:650–9.